Literature DB >> 11602342

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

C Cadwell1, G P Zambetti.   

Abstract

The tumor suppressor p53 plays a central role in the protection against DNA damage and other forms of physiological stress primarily by inducing cell cycle arrest or apoptosis. Mutation of p53, which is the most frequent genetic alteration detected in human cancers, inactivates these growth regulatory functions and causes a loss of tumor suppressor activity. In some cases, mutation also confers tumor-promoting functions, such as the transcriptional activation of genes involved in cell proliferation, cell survival and angiogenesis. Consequently, cells expressing some forms of mutant p53 show enhanced tumorigenic potential with increased resistance to chemotherapy and radiation. Our current understanding of these activities is summarized in this review. By dissecting out mechanistic differences between wild-type and mutant p53 activities, it may be possible to develop therapeutics that restore tumor suppressor function to mutant p53 or that selectively inactivate mutant p53 tumor-promoting functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602342     DOI: 10.1016/s0378-1119(01)00696-5

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  70 in total

1.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

2.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

3.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

4.  Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

Authors:  Heidi Sankala; Catherine Vaughan; Jing Wang; Sumitra Deb; Paul R Graves
Journal:  Arch Biochem Biophys       Date:  2011-05-20       Impact factor: 4.013

5.  On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

Authors:  Karim M ElSawy; Chandra S Verma; Thomas L Joseph; David P Lane; Reidun Twarock; Leo S D Caves
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

6.  Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations.

Authors:  Songjian Lu; Chunhui Cai; Gonghong Yan; Zhuan Zhou; Yong Wan; Vicky Chen; Lujia Chen; Gregory F Cooper; Lina M Obeid; Yusuf A Hannun; Adrian V Lee; Xinghua Lu
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

7.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 8.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Transcription factor ZBP-89 is required for STAT1 constitutive expression.

Authors:  Longchuan Bai; Juanita L Merchant
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

10.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.